Effect of nivazol in Nelson’s syndrome

Joanna A. Ball, Gareth Williams, Tom H. Yeo and G.F. Joplin

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS, UK.

Summary: We report the use of nivazol in a patient with Nelson’s syndrome. Nivazol was highly effective in reducing ACTH secretion but, contrary to reports of its use in other primates, in our patient nivazol did have systemic glucocorticoid effects.

Introduction

Nelson’s syndrome, comprising a pituitary corticotroph tumour, high plasma adrenocorticotropic hormone (ACTH) concentrations and hyperpigmentation, develops in up to 80% of patients following bilateral adrenalectomy for Cushing’s disease. Some cases progress despite attempted hypophysectomy, irradiation or the available medical treatments (cyproheptadine, bromocriptine, and sodium valproate). We have treated one such case with nivazol (Sterling-Winthrop Research Institute), a synthetic steroid which reduces ACTH secretion both in vitro from corticotroph tumours, and in vivo in monkeys without exerting systemic glucocorticoid effects.

Case report

A 22 year old man with Cushing’s disease underwent subtotal adrenalectomy in 1953 and total adrenalectomy in 1956. Two years later, he presented with bitemporal visual loss, 3rd and 4th cranial nerve palsies and hyperpigmentation. He underwent transfrontal hypophysectomy and external beam irradiation for a locally invasive mucoid cell adenoma, but pigmentation progressed despite interstitial 90Y irradiation (1972 and 1974, total dose 200,000 cGy), and he became severely depressed. ACTH levels remained grossly elevated, with no consistent fall with cyproheptadine (24 mg/day), sodium valproate (1500 mg/day) or bromocriptine (40 mg/day). In 1986, computed tomographic (CT) scan showed residual pituitary tumour with extensions laterally and into the sphenoid sinus.

The present study was carried out in hospital in 1986. His usual replacement treatment with hydrocortisone 20 mg (0700 h), 10 mg (1400 h), 10 mg (1800 h), fludrocortisone 0.1 mg alternate days, thyroxine 200 μg daily and testosterone undecanoate 40 mg t.d.s., was continued. Forty-eight hour plasma cortisol and ACTH profiles (4-hourly samples) were measured before nivazol treatment, after 1 week of low-dose oral nivazol (200 mg at 0800 and 2000 h) and after 6 weeks of high-dose nivazol (400 mg at 0800 and 2000 h). Blood samples for ACTH assay were collected into plastic lithium-heparin tubes containing aprotinin (400 kIU/ml blood). Plasma was separated immediately by centrifugation at 4°C, extracted on to Vycor glass and ACTH was measured by double-antibody radioimmunoassay. The intra- and inter-assay coefficients of variation were 10% at 500 ng/l and <20% at 700 ng/l.

Serial photographs showed strikingly reduced skin pigmentation after both low and high dosages, being evident within 2 weeks. Nivazol treatment also significantly reduced mean plasma ACTH levels from 4244 ± 1093 (s.e.m.) ng/l (pre-treatment) to 1198 ± 257 ng/l with low dosage (P < 0.02 by paired t-test, n = 12) and still further to 849 ± 123 ng/l (P < 0.01, n = 12) with high dosage (Figure 1). Mean cortisol concentrations were unchanged (pre-treatment, 425 ± 96 nmol/l; low dosage, 455 ± 95 nmol/l; high dosage, 559 ± 107 nmol/l). Pituitary tomography showed no change in sellar size over the treatment period of 8 months. Biochemical and haematological indices were unchanged.

Nivazol was initially well tolerated and ACTH levels fell to the lowest values ever recorded in this patient (333 ± 147 ng/l), but after 10 weeks the patient developed facial plethora, weight gain, proximal myopathy and depression. These Cushingoid features remained for a further 10
Nivazol was clearly highly effective in decreasing plasma ACTH concentrations and pigmentation. Its mechanism of action is probably similar to that of hydrocortisone. Both steroids directly inhibit in vitro ACTH secretion from corticotroph tumour cells removed from patients with Nelson's syndrome and block stimulation of ACTH release by ovine corticotrophin releasing factor and arginine vasopressin. As therapeutic plasma nivazol levels are lower than those effective in vitro, nivazol (like hydrocortisone) may also act on the hypothalamus. The unchanged cortisol profiles argue against an effect on hydrocortisone metabolism. We cannot assess whether nivazol had additional tumour stabilizing or shrinkage effects. Nivazol had significant Cushingoid side effects in our patient, even though proportionately much higher doses (1 g/day) in monkeys suppressed the hypothalamic-pituitary-adrenal axis without exerting peripheral glucocorticoid effects. It remains to be investigated whether dosages of <400 mg/day may be therapeutically useful without causing these side effects.

Acknowledgement

We would like to thank Karen F. Stringer, B.Sc., Project Leader, Sterling-Winthrop Research and Development, Sterling-Winthrop House, Surbiton, Surrey, for the supply of nivazol and for helpful discussions.

References

Effect of nivazol in Nelson's syndrome.

J. A. Ball, G. Williams, T. H. Yeo and G. F. Joplin

doi: 10.1136/pgmj.64.749.220

Updated information and services can be found at:
http://pmj.bmj.com/content/64/749/220

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/